Evidence map›Paper›PMID 31637480›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2019

The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu.

Hans Dieter Nischalke, Philipp Lutz, Eva Bartok, Benjamin Krämer, Bettina Langhans, Regina Frizler, Thomas Berg, Jochen Hampe, Stephan Buch, Christian Datz and 5 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Genetic Variation ofInternational journal of molecular sciences · 2022
    Article
  6. Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH.Liver international : official journal of the International Association for the Study of the Liver · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Hans Dieter NischalkeDepartment of Internal Medicine I, University Hospital, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. nischalke@ukbonn.de.ORCID 0000-0002-3457-0023
Philipp LutzDepartment of Internal Medicine I, University Hospital, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Eva BartokInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital, University of Bonn, Bonn, Germany.
Benjamin KrämerDepartment of Internal Medicine I, University Hospital, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Bettina LanghansDepartment of Internal Medicine I, University Hospital, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Regina FrizlerDepartment of Internal Medicine I, University Hospital, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Thomas BergDepartment of Gastroenterology, University Hospital Leipzig, Leipzig, Germany.
Jochen HampeMedical Department 1, University Hospital Dresden, TU Dresden, Dresden, Germany.
Stephan BuchMedical Department 1, University Hospital Dresden, TU Dresden, Dresden, Germany.
Christian DatzDepartment of Internal Medicine, Hospital Oberndorf, Teaching Hospital of the Paracelsus Private University of Salzburg, Salzburg, Austria.
Felix StickelDepartment of Gastroenterology and Hepatology, University Hospital of Zürich, Zürich, Switzerland.
Gunther HartmannInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital, University of Bonn, Bonn, Germany.
Christian P StrassburgDepartment of Internal Medicine I, University Hospital, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Jacob NattermannDepartment of Internal Medicine I, University Hospital, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Ulrich SpenglerDepartment of Internal Medicine I, University Hospital, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
University of Bonn · DETechnische Universität Dresden · DEUniversity Hospital Leipzig · DEUniversity Hospital of Zurich · CHUniversity of Salzburg · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The I148M variant of the Patatin-like phospholipase domain-containing 3 (PNPLA3) protein is associated with an increased risk for liver inflammation and hepatocellular carcinoma (HCC), but the underlying mechanism is unknown. We hypothesized that enhanced CXC chemokine secretion mediates hepatic inflammation that accelerates development of HCC. Expandable primary human (upcyte®) hepatocytes and human PLC/PRF/5 hepatoma cells were lentivirally transduced with both PNPLA3 I148M variants and stimulated with lipids. Cytokine levels in culture supernatant and patient sera (n = 80) were analyzed by ELISA. Supernatants were assessed in transmigration experiments, tube formation, and proliferation assays. In vitro, lipid stimulation of transduced hepatocytes dose-dependently induced the production of interleukin-8 and CXCL1 in hepatocytes carrying the PNPLA3 148M variant. In line, sera from PNPLA3 148M-positive patients with alcoholic liver cirrhosis contained higher levels of interleukin-8 and CXCL1 than patients with wild-type PNPLA3. Supernatants from lipid-stimulated hepatocytes with the PNPLA3 148M variant induced enhanced migration of white blood cells, angiogenesis, and cell proliferation in comparison with supernatants from wild-type hepatocytes via CXC receptors 1 and 2. Increased production of interleukin-8 and CXCL1 by hepatocytes carrying the PNPLA3 148M variant contributes to a pro-inflammatory and tumorigenic milieu in patients with alcoholic liver disease. KEY MESSAGES: The PNPLA3 148M variant is associated with cirrhosis and hepatocellular carcinoma. Lipid stimulation of hepatocytes with this variant induces IL-8 and CXCL1. Supernatants from hepatocytes with this variant promote migration and angiogenesis. Sera from patients with this variant contained enhanced levels of IL-8 and CXCL1. The PNPLA3 148M variant contributes to a tumorigenic milieu via IL-8 and CXCL1.

Indexed as

AcyltransferasesCarcinoma, HepatocellularChemokine CXCL1Chemokine CXCL5Chemokines, CXCGenetic Predisposition to DiseaseHepatocytesHumansInterleukin-8LipaseLiver NeoplasmsMembrane ProteinsPhospholipases A2, Calcium-IndependentPlatelet Factor 4AcyltransferasesChemokine CXCL1Chemokine CXCL5Chemokines, CXCInterleukin-8LipaseMembrane ProteinsPhospholipases A2, Calcium-IndependentPlatelet Factor 4PNPLA3 protein, humanalcoholic liver diseasecirrhosisCXCL1HCCIL-8PNPLA3 148Mrs738409

Identifiers

PMID31637480
OpenAlexW2980606554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.